Department of Infectious Diseases, General Hospital, Toulon, France.
AIDS Res Ther. 2012 Aug 1;9(1):23. doi: 10.1186/1742-6405-9-23.
The 2012 International Symposium on HIV and Emerging Infectious Diseases (ISHEID) provided a forum for investigators to hear the latest research developments in the clinical management of HIV and HCV infections as well as HIV-1 reservoirs and cure research. Combined anti-retroviral therapy (c-ART) has had a profound impact on the disease prognosis of individuals living with HIV-1 infection. However, although these anti-retroviral regimens are able to reduce plasma viremia to below the limits of detection for sustained periods of time, there is a rapid recrudescence in plasma viremia if treatment is interrupted. Therefore, despite this potent anti-retroviral suppression, HIV-1 is able to persist within the infected individual. The main 2012 ISHEID theme was, hence "searching for an HIV cure". In this report we not only give details on this main topic of the 2012 ISHEID but also summarize what has been discussed in the areas of HIV epidemiology, access to care, antiretroviral therapy management and recent progress in the therapy of HCV infection in patients with HIV.
2012 年国际艾滋病和新发传染病研讨会（ISHEID）为研究人员提供了一个论坛，让他们了解 HIV 和 HCV 感染的临床管理以及 HIV-1 储存库和治愈研究的最新研究进展。联合抗逆转录病毒疗法（c-ART）对 HIV-1 感染个体的疾病预后产生了深远影响。然而，尽管这些抗逆转录病毒方案能够在长时间内将血浆病毒载量降低到检测不到的水平，但如果中断治疗，血浆病毒载量会迅速回升。因此，尽管这种强效的抗逆转录病毒抑制作用，HIV-1 仍能在感染者体内持续存在。2012 年 ISHEID 的主要主题是，“寻找 HIV 治愈方法”。在本报告中，我们不仅详细介绍了 2012 年 ISHEID 的这一主要主题，还总结了 HIV 流行病学、获得治疗机会、抗逆转录病毒治疗管理以及 HIV 合并 HCV 感染患者治疗方面的最新进展。
